Steady growth meets restructuring costs
- STERIS is a picks and shovels healthcare company, selling sterilizers, consumables, services, and contract sterilization.
- First quarter fiscal 2027 revenue grew across all three segments, led by a 7.9% organic gain in Life Sciences.
- The company is consolidating chemistry manufacturing into a new North Carolina hub, which will cost up to $70 million upfront.
- AST segment revenue grew, but actual volume declined, raising questions about localized demand softness.
- The Illinois ethylene oxide legal overhang is smaller after a $48.2 million settlement for substantially all Cook County personal injury claims.
Steady demand, harder costs
STERIS maintained its momentum into the first quarter of fiscal 2027. All three segments posted constant currency organic growth. Healthcare grew 6.4%, Life Sciences grew 7.9%, and Applied Sterilization Technologies grew 4.7%. However, the AST growth relied on price increases to hide a drop in volume.
The bull case centers on steady demand for clean rooms, sterile tools, and sterilized products. Hospitals and drug makers are captive buyers. Once STERIS sells the equipment, it earns recurring revenue from consumables and services tied to that installed base. The company generates strong cash flow, which supported a new $1.0 billion share repurchase program in May 2026. Management believes a newly announced manufacturing hub in North Carolina will eventually improve margins.
The bear case focuses on near term costs. Gross margins face ongoing pressure from tariffs and inflation. Adding to the friction, the North Carolina consolidation will cost between $55 million and $70 million before taxes and requires closing facilities in Missouri and Minnesota. The AST volume decline also suggests pockets of weakness.
Finn scores the company a 3.3 overall. The business is financially healthy, but the stock needs to prove that margins can expand while the company handles facility closures and inflation.
Installed base, repeat spend
STERIS makes money in three ways by selling capital equipment, selling consumables used with that equipment, and providing services. Capital equipment includes sterilizers, surgical tables, automated endoscope reprocessors, and systems used in drug manufacturing. Consumables include cleaning chemistries, sterility assurance products, endoscopy accessories, and other items customers keep buying.
The model works because the first equipment sale can lead to years of follow-on revenue. A hospital that buys sterilization equipment also needs service, maintenance, parts, and supplies. A medical device company that uses STERIS for contract sterilization often needs that service every time it ships product.
This repeat-spend base makes STERIS more stable than a pure equipment seller. Still, the company is not immune to cycles. When hospitals, pharma companies, or device makers delay large projects, capital equipment orders can slow.
What STERIS sells
Healthcare equipment
STERIS sells sterilizers, surgical tables, lights, operating room systems, and endoscope reprocessors to hospitals and care sites. These are large purchases, so timing can move quarter to quarter.
Healthcare consumables
Consumables include sterilization chemistries, sterility assurance products, endoscopy accessories, instruments, and cleaning products. Demand is tied to procedure volumes and daily hospital work.
Healthcare services
STERIS provides maintenance, installation, instrument repair, scope repair, and outsourced reprocessing. These services help turn the installed equipment base into repeat revenue.
Applied Sterilization Technologies
AST provides contract sterilization and lab testing for medical device and biopharma customers. It is a high-margin segment, with fiscal 2026 operating margin of 46.1%.
Life Sciences equipment
This line sells equipment for aseptic drug manufacturing and critical environments. It rebounded in fiscal 2026, with Life Sciences capital revenue up 15.5%.
Life Sciences consumables and services
These products and services support pharma and research customers after equipment is installed. In fiscal 2026, Life Sciences consumables grew 7.6% and services grew 4.9%.
Healthcare carries the mix
Segment shares use first quarter fiscal 2027 revenue from the Form 10-Q. Healthcare is the largest piece, so hospital procedure volumes and hospital capital budgets matter most.
What could go wrong
Restructuring and supply chain disruption
Medium impact · Medium oddsSTERIS is moving its chemistry manufacturing to a new Center of Excellence in North Carolina. This requires closing facilities in St. Louis and Plymouth. The move carries $55 million to $70 million in expected pre-tax charges and could disrupt supply chains if execution falters.
Localized volume declines in AST
Medium impact · Medium oddsWhile the AST segment grew revenue in the first quarter of fiscal 2027, it suffered a volume decline that was offset by price increases. This suggests localized softness in medical device or biopharma demand.
Tariffs and inflation eat the price gains
High impact · Medium oddsSTERIS raised prices and improved productivity in fiscal 2026, but tariffs and inflation still held back gross margin. If tariff pressure rises or cost inflation stays sticky, earnings growth could lag revenue growth.
Ethylene oxide claims move beyond Illinois
High impact · Medium oddsSTERIS agreed to pay up to $48.2 million to resolve substantially all personal injury claims related to ethylene oxide exposure pending in Cook County, Illinois. That removed a major known overhang. The open question is whether other jurisdictions or regulators create new costs.
Capital equipment turns down again
Medium impact · Medium oddsLife Sciences capital equipment recovered in fiscal 2026, but capital orders are still cyclical. Large hospital, pharma, or device maker projects can be delayed when budgets tighten.
In one breath
What does STERIS do?
STERIS helps hospitals, medical device companies, and drug makers keep products and care settings sterile. It sells sterilization equipment, consumables, maintenance services, contract sterilization, and life sciences products.
Why is STERIS considered recurring revenue?
Many customers keep buying consumables and services after they buy STERIS equipment. The company also earns service revenue from contract sterilization and equipment maintenance, which tends to repeat with customer activity.
What changed most recently for STERIS?
The company announced a plan to consolidate its formulated chemistries manufacturing into a new Center of Excellence in North Carolina. In the first quarter of fiscal 2027, all three segments grew, though the AST segment saw a drop in volume.
What is the biggest risk for STERIS stock?
The biggest near-term risks are margin pressure from inflation and execution risks tied to its new manufacturing consolidation plan.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- September 13, 2026
- Score data
- September 27, 2026
- Reviewed by
- Shivam Bharuka
Comparable Medical Devices companies
Companies near STERIS plc in Finn's Medical Devices industry ranking.
